Theralase Technologies Inc (TLTFF)

[123414]

Theralase Releases AGM Videos


Toronto, Ontario (FSCwire) - Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a clinical-stage pharmaceutical company dedicated to the research and development of light-activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations used to safely and effectively destroy cancer is pleased to announce the release of three videos presented at the completion of the Company’s Annual and Special Meeting, held at the Company’s corporate office on June 22, 2018.

The videos are as follows:

Girish Kulkarni MD, Surgeon-scientist affiliated with the Department of Surgery, Faculty of Medicine at the University of Toronto discusses the successful completion of the Phase Ib Non-Muscle Invasive Bladder Cancer (“NMIBC”) clinical study –

Michael Jewett MD, Professor of Surgery (Urology) at the University of Toronto discusses the proposed design of the Phase II NMIBC clinical study –

Manjunatha Ankathatti Munegowda, Ph.D., DVM, Research Scientist, Theralase discusses the potential opportunities for the Company in regards to new oncological targets, such as Glio Blastoma Multiforme (“GBM”), a deadly form of brain cancer, and Non-Small Cell Lung Cancer (“NSCLC”) –

Arkady Mandel, Interim Chief Executive Officer and Chief Scientific Officer of Theralase stated that, “Theralase is delighted to be associated with Dr. Kulkarni and Dr. Jewett and their combined expertise in the field of uro-oncology. Their experience and guidance was key in assisting Theralase to successfully complete a Phase Ib NMIBC clinical study, ending the study early after the treatment of only six patients. The Phase Ib NMIBC clinical study successfully met its primary, secondary and exploratory outcome measures of safety and tolerability, pharmacokinetics (movement and exit of drug within tissue) and efficacy, respectively, at ninety days post-treatment. The Company will report out on the exploratory endpoint of efficacy for patient five and six, when sufficient clinical data has been collected to provide this information. We are pleased with the results of our preclinical programs for our patented, rutherrin-based, Photo Dynamic Therapy (“PDT”). The preclinical data presented by Dr. Munegowda supports the opportunity to diversify Theralase’s PDT technology into the treatment of GBM and NSCLC. These results are planned to be further validated in human clinical studies.”

About Theralase Technologies Inc.
https://app.quotemedia.com/quotetools/newsStoryPopup.go?storyId=7909670196872586&topic=TLTFF&symbology=null&cp=null&webmasterId=90338